Literature DB >> 25093228

Paraneoplasia, cancer development and immunity: what are the connections?

Louis Chesler.   

Abstract

Paraneoplasia literally means conditions adjacent to, or associated with, abnormal cancerous tissue growth. In this Comment article, I discuss what the immune-mediated paraneoplasias teach us about the immune response and cancer development.

Entities:  

Mesh：

Year:  2014        PMID： 25093228     DOI： 10.1038/nrc3766

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  9 in total

Review 1.  Paraneoplastic syndromes involving the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  N Engl J Med       Date:  2003-10-16       Impact factor: 91.245

Review 2.  Update on diagnosis, treatment, and prognosis in opsoclonus-myoclonus-ataxia syndrome.

Authors:  Mark P Gorman
Journal:  Curr Opin Pediatr       Date:  2010-12       Impact factor: 2.856

Review 3.  Cancer immunoediting: from immunosurveillance to tumor escape.

Authors:  Gavin P Dunn; Allen T Bruce; Hiroaki Ikeda; Lloyd J Old; Robert D Schreiber
Journal:  Nat Immunol       Date:  2002-11       Impact factor: 25.606

Review 4.  Paraneoplastic syndromes affecting the nervous system.

Authors:  Robert B Darnell; Jerome B Posner
Journal:  Semin Oncol       Date:  2006-06       Impact factor: 4.929

5.  Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group.

Authors:  R Cooper; Y Khakoo; K K Matthay; J N Lukens; R C Seeger; D O Stram; R B Gerbing; A Nakagawa; H Shimada
Journal:  Med Pediatr Oncol       Date:  2001-06

6.  Increased prevalence of autoimmune disorders and autoantibodies in parents of children with opsoclonus-myoclonus syndrome (OMS).

Authors:  I Krasenbrink; V Fühlhuber; I Juhasz-Boess; E Stolz; A Hahn; M Kaps; B Hero; F Blaes
Journal:  Neuropediatrics       Date:  2007-06       Impact factor: 1.947

7.  DNA vaccination with HuD inhibits growth of a neuroblastoma in mice.

Authors:  A F Carpentier; M R Rosenfeld; J Y Delattre; R G Whalen; J B Posner; J Dalmau
Journal:  Clin Cancer Res       Date:  1998-11       Impact factor: 12.531

Review 8.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728

9.  Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence.

Authors:  Timothy Kottke; Nicolas Boisgerault; Rosa Maria Diaz; Oliver Donnelly; Diana Rommelfanger-Konkol; Jose Pulido; Jill Thompson; Debabrata Mukhopadhyay; Roger Kaspar; Matt Coffey; Hardev Pandha; Alan Melcher; Kevin Harrington; Peter Selby; Richard Vile
Journal:  Nat Med       Date:  2013-11-17       Impact factor: 53.440
  9 in total
  1 in total

1.  Improved Prognosis and Increased Tumor-Infiltrating Lymphocytes in Patients Who Have SCLC With Neurologic Paraneoplastic Syndromes.

Authors:  Wade T Iams; Eileen Shiuan; Catherine B Meador; Marc Roth; Jennifer Bordeaux; Christine Vaupel; Kelli L Boyd; IlaSri B Summitt; Lucy L Wang; Joseph T Schneider; Jeremy L Warner; Zhiguo Zhao; Christine M Lovly
Journal:  J Thorac Oncol       Date:  2019-06-12       Impact factor: 15.609
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.